Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

[1]  P. Roques,et al.  Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera , 2022, JCI insight.

[2]  D. Gubler,et al.  The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines , 2022, PLoS neglected tropical diseases.

[3]  S. Manzoor,et al.  The global emergence of Chikungunya infection: An integrated view , 2021, Reviews in medical virology.

[4]  A. Wilcox,et al.  Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020–21 , 2021, Research square.

[5]  N. Wressnigg,et al.  Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. , 2020, The Lancet. Infectious diseases.

[6]  G. Ippolito,et al.  Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention. , 2019, Infectious disease clinics of North America.

[7]  C. Weinberg,et al.  Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study , 2019, BMJ.

[8]  L. Visser,et al.  Long-Term Protection After Fractional-Dose Yellow Fever Vaccination , 2018, Annals of Internal Medicine.

[9]  P. Roques,et al.  Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. , 2017, JCI insight.

[10]  B. Hoen,et al.  French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. , 2015, Medecine et maladies infectieuses.

[11]  A. Nisalak,et al.  High Rate of Subclinical Chikungunya Virus Infection and Association of Neutralizing Antibody with Protection in a Prospective Cohort in The Philippines , 2015, PLoS neglected tropical diseases.

[12]  Scott C Weaver,et al.  Chikungunya virus and prospects for a vaccine , 2012, Expert review of vaccines.

[13]  P. Gasque,et al.  Arthritogenic alphaviruses—an overview , 2012, Nature Reviews Rheumatology.

[14]  Kevin Lang,et al.  Trends in Self-reported Spontaneous Abortions: 1970–2000 , 2012, Demography.

[15]  A. P. Adams,et al.  Attenuation of Chikungunya Virus Vaccine Strain 181/Clone 25 Is Determined by Two Amino Acid Substitutions in the E2 Envelope Glycoprotein , 2012, Journal of Virology.

[16]  Nicolas Gangneux,et al.  Prophylaxis and Therapy for Chikungunya Virus Infection , 2009, The Journal of infectious diseases.

[17]  K. Ezzedine,et al.  Post-Epidemic Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated Factors over a 15-Month Period , 2009, PLoS neglected tropical diseases.

[18]  P. Parola,et al.  Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. , 2008, The Medical clinics of North America.

[19]  E. Caumes,et al.  Chikungunya Infection in Travelers , 2006, Emerging infectious diseases.

[20]  T. Monath,et al.  Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. , 2002, The American journal of tropical medicine and hygiene.

[21]  P. Repik,et al.  Development of an attenuated strain of chikungunya virus for use in vaccine production. , 1986, Vaccine.

[22]  P. Bartelloni,et al.  Production and evaluation of a formalin-killed Chikungunya vaccine. , 1971, Journal of immunology.

[23]  Harry Jerome.  Production , 1929, American Journal of Sociology.

[24]  L. Rossen,et al.  Trends in Risk of Pregnancy Loss Among US Women, 1990-2011. , 2018, Paediatric and perinatal epidemiology.

[25]  S. Brighton.  Chikungunya virus infections. , 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.